between you and CSL Behring with respect to your use of this Web site. You may, however, be subject to
additional terms that may apply when you access particular services or materials on certain areas in this
without prior notification. Your use of this Web site constitutes your agreement to this right. Indicated at the
As a leading innovation-driven Pharmaceutical company, CSL Behring is committed to playing a
major role in improving the quality of life for patients with rare and serious disorders. This
site gives you insights into CSL Behring, its worldwide subsidiaries, and related industry information.
To facilitate the use of this site, we provide you with tailored information dependent upon the purpose
of your respective visit, be it as a patient, healthcare professional, investor or prospective employee.
PLEASE NOTE THAT NO INFORMATION IN THIS SITE IS PROVIDED WITH THE INTENTION OF NOR SHOULD IT BE VIEWED
AS GIVING MEDICAL ADVICE OR INSTRUCTION ON THE CORRECT USE OF PRODUCTS MANUFACTURED OR DISTRIBUTED BY CSL Behring.
CSL Behring offers the information on this Web site for general educational and informational purposes only.
This information is not intended as a substitute for advice, treatment, or recommendations from health care
professionals. It is important to follow the advice of your physician and other health care professionals
regarding your individual medical and health care needs. Please consult with your physician or other health
care professional before using any drug product discussed within this Web site. CSL Behring is not engaged in
rendering medical advice or services.
Scope of Use
Except for our site visitors’ downloading of a single copy of this site for informational, non-commercial purposes,
no content on this site is to be copied, downloaded, or stored for any other purpose, nor is such content to be
disseminated to any party or for any purpose, without the express, written permission of CSL Behring. CSL Behring
retains the right, at any time, without prior notice, and with or without cause, to restrict or terminate a visitor’s
use of or access to this site.
No Guarantee or Warranty
CSL BEHRING ENDEAVORS TO KEEP THIS SITE UP-TO-DATE. HOWEVER, THE CONTENT ON THIS SITE IS PROVIDED WITHOUT WARRANTY
OF ANY KIND EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON-INFRINGEMENT. CONTENT ON THIS SITE IS PROVIDED ON
AN “AS IS” AND “AS AVAILABLE” BASIS. CSL BEHRING MAKES NO REPRESENTATIONS OR WARRANTIES REGARDING THIS SITE AND ITS
CONTENT REGARDING ACCURACY, COMPLETENESS, CURRENCY, OR RELIABILITY, OR THAT THE USE OF THIS SITE WILL BE UNINTERRUPTED
OR ERROR-FREE. VISITORS ARE RESPONSIBLE FOR THE VERIFICATION OF ANY INFORMATION BEFORE ACTING IN RELIANCE UPON SUCH
INFORMATION, AND USE OF THIS SITE IS AT THE SOLE RISK OF VISITORS TO IT. VISITORS ARE ALSO RESPONSIBLE FOR TAKING ALL
PRECAUTIONS NECESSARY TO ENSURE THAT ANY CONTENT THAT IS OBTAINED IS VIRUS-FREE. TO THE EXTENT THAT APPLICABLE STATE
LAW RESTRICTS OR LIMITS IMPLIED WARRANTIES, ONE OR MORE OF THE ABOVE LIMITATIONS MAY NOT APPLY IN PARTICULAR CASES.
Limitation of Liability
CSL BEHRING SPECIFICALLY DISCLAIMS ANY LIABILITY, WHETHER BASED IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE,
FOR ANY DAMAGES, WHETHER DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR SPECIAL, ARISING OUT OF OR IN ANY WAY
CONNECTED WITH ACCESS TO OR USE OF THE SITE AND ITS CONTENT, REGARDLESS OF WHETHER OR NOT CSL BEHRING HAS BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION OF LIABILITY INCLUDES, BUT IS NOT LIMITED TO, ANY
RELIANCE BY ANY PARTY ON ANY CONTENT THAT IS OBTAINED DIRECTLY OR INDIRECTLY THROUGH THE USE OF THIS SITE, AS WELL
AS ANY DAMAGES THAT ARISE AS A RESULT OF VIRUSES, INTERRUPTIONS IN TELECOMMUNICATIONS CONNECTIONS TO THE SITE, OR
DELAYS, MISTAKES, OR OMISSIONS IN TRANSMISSIONS TO OR FROM THE VISITOR, WHETHER CAUSED BY THEFT, DESTRUCTION, NEGLIGENCE,
WAR, TERRORISM, ACTS OF GOD, TELECOMMUNICATIONS FAILURE, OR ANY UNAUTHORIZED ACCESS TO THE SITE OR ITS INFORMATION.
VISITORS USE THIS SITE AND ITS CONTENTS AT THEIR OWN RISK.
Links to Other Sites
For the convenience of our visitors, CSL Behring provides links to other Web sites. However, certain links on
this site lead to resources located on servers maintained by third parties over whom CSL Behring has no control.
CSL Behring is not responsible for third party content or the consequences of one of our visitor’s use thereof;
consequently, access to and use of such sites is at the risk of visitors to such sites. Such links do not and
should not imply CSL Behring’s endorsement of material on any other site. CSL Behring expressly disclaims any
liability with regard to access to such sites.
and hold harmless CSL Behring (including its officers, directors, employees, agents, and licensees) from
any liability that arises from or is otherwise related to such violation and/or misuse, including but not
limited to expenses, costs, and attorneys’ fees.
Expert Advice or Opinion
As a useful resource to our visitors this site may contain expert opinions. Information in this site identified
as expert opinion, or accessed from this site by hyperlink, represents the opinions of these respective experts,
which are not necessarily those of CSL Behring. Such experts are not employees of CSL Behring and do not receive
any compensation from CSL Behring for the use of their opinions. CSL Behring does not endorse, and is not responsible
for, the accuracy or completeness of any information or opinions set forth in such materials. Please note that expert
advice reflects only the personal view of that expert — in no case shall it be regarded as the opinion or responsibility of CSL Behring.
Country-specific Product Information
CSL Behring provides information with respect to its global and local pharmaceutical business that might not be relevant
to every visitor around the world. For example, trademarks used for certain products may differ from country to country.
Furthermore, in some countries regulatory authorities may approve products for sale with different indications, dosages
and restrictions. If CSL Behring’s products, programs and services mentioned in this site are not available in your country,
any such reference does not imply that CSL Behring intends to announce these products, programs or services in your country.
Consult your local CSL Behring contact or your physician for further information as to the availability of our products in your
country. Due to laws specific to different jurisdictions, we may not be able to provide all visitors with information on our
prescription drugs. CSL Behring intends to disclose country-specific product information primarily to healthcare professionals
and, only where permissible, to the general public.
In any forum for discussion on this site, CSL Behring expects the participants to observe common rules for communication,
such as mutual respect for others. Visitors must not distribute or publish any offensive, abusive, indecent, defamatory
or obscene material or any material that breaches a third party’s intellectual property rights.
Information Deemed Non-Confidential
be non-confidential and non-proprietary. Subject to applicable laws, CSL Behring shall be free to use any such information,
including but not limited to ideas, concepts, know-how, or techniques, contained in such communication for any purpose, without
compensation to you and without identifying the source, and you grant to CSL Behring the irrevocable right to copy, modify,
any communication from you to CSL Behring will be submitted or otherwise provided to CSL Behring in accordance with applicable
law, including but not limited to, obtaining any necessary consents or authorizations from individuals prior to the submission
of health or other personal information. You will not submit anything to this site that contains any viruses or other software
that may adversely affect the operation of this site, or another party’s computer or information system.
This site contains press releases and other news regarding CSL Behring, which CSL Behring believed to be accurate as of the date
that it was prepared and/or posted on this site. Nevertheless, CSL Behring hereby disclaims any obligation to update such press
releases and other news, and/or the information contained therein. In no event should any information about companies, other than
CSL Behring, be relied upon as having been provided by CSL Behring, nor does the appearance of such information about other companies
on this site constitute an endorsement by CSL Behring of the accuracy or completeness of such information.
Security Obligations of Visitors
In some cases, visitors to this site may be required to register or to obtain a password prior to gaining access to certain provisions
of the site or to certain services provided by the site. If so, it is the responsibility of the visitor to ensure that the confidentiality
of the registration information and password is maintained. The visitor shall be responsible for all uses of such password, whether or not
the visitor has authorized such use.
exclusively by the state and federal courts of the Commonwealth of Pennsylvania.
This Web site can be accessed from the United States and other countries worldwide. Since the laws of each State or country may differ,
you agree that the statutes and laws of the Commonwealth of Pennsylvania, without regard to any principles of conflicts of law, will apply
to all matters relating to the use of this site.
HEMGENIX®, etranacogene dezaparvovec-drlb, is a one-time gene therapy for the treatment of adults with hemophilia B who:
Currently use Factor IX prophylaxis therapy, or
Have current or historical life-threatening bleeding, or
Have repeated, serious spontaneous bleeding episodes.
HEMGENIX is administered as a single intravenous infusion and can be administered only once.
What medical testing can I expect to be given before and after administration of HEMGENIX?
To determine your eligibility to receive HEMGENIX, you will be tested for Factor IX inhibitors. If this test result is positive, a retest will be performed 2 weeks later. If both tests are positive for Factor IX inhibitors, your doctor will not administer HEMGENIX to you. If, after administration of HEMGENIX, increased Factor IX activity is not achieved, or bleeding is not controlled, a post-dose test for Factor IX inhibitors will be performed.
HEMGENIX may lead to elevations of liver enzymes in the blood; therefore, ultrasound and other testing will be performed to check on liver health before HEMGENIX can be administered. Following administration of HEMGENIX, your doctor will monitor your liver enzyme levels weekly for at least 3 months. If you have preexisting risk factors for liver cancer, regular liver health testing will continue for 5 years post-administration. Treatment for elevated liver enzymes could include corticosteroids.
What were the most common side effects of HEMGENIX in clinical trials?
In clinical trials for HEMGENIX, the most common side effects reported in more than 5% of patients were liver enzyme elevations, headache, elevated levels of a certain blood enzyme, flu-like symptoms, infusion-related reactions, fatigue, nausea, and feeling unwell. These are not the only side effects possible. Tell your healthcare provider about any side effect you may experience.
What should I watch for during infusion with HEMGENIX?
Your doctor will monitor you for infusion-related reactions during administration of HEMGENIX, as well as for at least 3 hours after the infusion is complete. Symptoms may include chest tightness, headaches, abdominal pain, lightheadedness, flu-like symptoms, shivering, flushing, rash, and elevated blood pressure. If an infusion-related reaction occurs, the doctor may slow or stop the HEMGENIX infusion, resuming at a lower infusion rate once symptoms resolve.
What should I avoid after receiving HEMGENIX?
Small amounts of HEMGENIX may be present in your blood, semen, and other excreted/secreted materials, and it is not known how long this continues. You should not donate blood, organs, tissues, or cells for transplantation after receiving HEMGENIX.